Avalon Globocare Corp
Company Profile
Business description
Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high-impact, transformative biotechnology, clinical applications, and healthcare facility management. The company has two reportable segments: the Lab Services MSO segment, which is the key revenue driver, and the AI generated Publishing segment. The Lab Services MSO segment was engaged in providing laboratory testing services. The company's core Technology Platforms are Precision Diagnostics; KetoAir breathalyzer device nanosensor technology; QTY protein design platform joint intellectual property with Massachusetts Institute of Technology (MIT); and Catch-Up Agentic AI Video Platform.
Contact
4400 Route 9 South
Suite 3100
FreeholdNJ07728
USAT: +1 732 780-4400
Sector
Real Estate
Stock type
Cyclical
Industry
Real Estate Services
Fiscal Year End
31 December 2026
Employees
2
Stocks News & Analysis
stocks
Is this the catalyst US tech giant needs?
stocks
ASX share plunges due to Iran related weakness
stocks
Investors punish this ASX player after acquisition
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,113.40 | 6.40 | 0.07% |
| CAC 40 | 8,186.78 | 72.82 | -0.88% |
| DAX 40 | 23,595.68 | 208.27 | -0.87% |
| Dow JONES (US) | 47,916.57 | 269.23 | -0.56% |
| FTSE 100 | 10,567.53 | 33.00 | -0.31% |
| HKSE | 25,660.85 | 232.69 | -0.90% |
| NASDAQ | 22,902.89 | 80.48 | 0.35% |
| Nikkei 225 | 56,502.77 | 421.34 | -0.74% |
| NZX 50 Index | 13,020.18 | 161.26 | -1.22% |
| S&P 500 | 6,816.89 | 7.77 | -0.11% |
| S&P/ASX 200 | 8,926.00 | 14.20 | 0.16% |
| SSE Composite Index | 3,988.56 | 2.33 | 0.06% |